Reunion Neuroscience Inc
Reunion Neuroscience Inc, based in Toronto, Ontario, is a clinical-stage biopharmaceutical company dedicated to advancing serotonergic psychedelic mental health therapies. Their mission is to develop innovative and patented FDA-approved solutions, starting with postpartum depression, that offer safe, fast-acting, and short-duration therapies for underserved mental health disorders.
With a vision of transforming the treatment of depression from management to cure, Reunion Neuroscience is committed to developing safer therapeutics that provide lasting antidepressive effects for individuals not adequately served by current standards of care. Their pioneering approach is rooted in leveraging decades of psychedelic research to address a range of mental health conditions.
Reunion Neuroscience's lead clinical-stage drug candidate, RE104, is a novel prodrug targeting the serotonin 2A receptor. This compound, based on psilocybin-like properties, shows promise in providing effective antidepressant effects. The company's team comprises industry entrepreneurs and scientific leaders dedicated to pushing the boundaries of neuroscience to create a world where mental and emotional well-being are paramount.
Generated from the website content
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.
